Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer

Basit Öğe Kaydı
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorKarhan, Ogur
dc.contributor.authorSezgin, Yasin
dc.contributor.authorBilen, Erkan
dc.date.accessioned2024-04-24T16:02:03Z
dc.date.available2024-04-24T16:02:03Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide regimen related toxicity is high, weekly regimens have been investigating. We aimed to compare the efficacy and safety of different concurrent chemotherapy regimens in the context. Methods A total of 225 patients with locally advanced, unresectable stage III NSCLC were included. Patients who were treated with weekly docetaxel-platin (DP), paclitaxel-platin (PP) and standard dose etoposide-platin (EP) chemotherapy regimens were selected and divided into groups for the comparison of toxicity, response rate, progression free survival (PFS), and overall survival (OS) times. Results There was a statistically significant difference between overall response rate of each treatment groups (DP: 96.1%, PP: 94% and EP: 76.7%,p < 0.001). The median PFS time of patients who were treated with DP, PP and EP was 16, 15 and 13.3 months, respectively (p = 0.435). The median OS time of patients treated with DP, PP and EP was 19.2, 29.7 and 28.3 months, respectively (p < 0.001). The rates of adverse events such as nausea, vomiting, neuropathy and anaphylaxis was similar. Grade 1-2 mucositis or esophagitis, anemia, pneumonitis were significantly higher in PP group than other groups. However, hematologic toxicities were higher in the EP group than other groups. Conclusions Compared to the weekly chemotherapy regimens with the standard dose, our study demonstrated similar PFS, but a prolonged OS with the EP regimen. The clinical response rate of weekly regimens was better than the full-dose regimen. Adverse events and toxicity rates were different and depended on the type of chemotherapy regimen used.en_US
dc.identifier.doi10.1007/s10147-020-01767-x
dc.identifier.endpage2024en_US
dc.identifier.issn1341-9625
dc.identifier.issn1437-7772
dc.identifier.issue12en_US
dc.identifier.pmid32797321
dc.identifier.scopus2-s2.0-85089390704
dc.identifier.scopusqualityQ1
dc.identifier.startpage2015en_US
dc.identifier.urihttps://doi.org/10.1007/s10147-020-01767-x
dc.identifier.urihttps://hdl.handle.net/11468/14594
dc.identifier.volume25en_US
dc.identifier.wosWOS:000559682600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer Japan Kken_US
dc.relation.ispartofInternational Journal of Clinical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectConcomitant Chemoradiotherapyen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectLocally Advanceden_US
dc.subjectDocetaxelen_US
dc.subjectPaclitaxelen_US
dc.subjectEtoposideen_US
dc.titleComparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung canceren_US
dc.titleComparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu